JIN-A01 / J Ints Bio - LARVOL DELTA

JInz Bio secures new pipelines JIN-A01 and JIN-A02 [Google translation] (Money Today) - "JInz Bio (formerly Josia Bio) announced on the 13th that it has secured new pipelines such as 'JIN-A01' and 'JIN-A02'....JIN-A01 is a substance that simultaneously targets exon 20 insertion mutations of EGFR (epithelial growth factor receptor) and HER2 (human epidermal growth factor receptor 2)....'The results of the previous study showed that JIN-A01's cell growth reduction efficacy was superior to that of the previously approved product for this indication,'....JIN-A02 is the 4th generation EGFR-TKI target material....'JIN-A02 showed more effective cancer cell killing and higher BBB permeability than the 3rd generation TKI currently in use in in vitro experiments on Del19, L858R, and T790M mutations, including EGFR C797S mutation.'"

Pipeline update • Preclinical • Oncology